Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nChroma Bio's CNS program focuses on the development of smaller, next-generation epigenetic editors specifically optimized for in vivo delivery to the central nervous system (CNS). These editors are designed to precisely modulate the expression of disease-relevant genes by modifying epigenetic marks—such as DNA methylation—without altering the underlying DNA sequence. This approach aims to provide a durable and potentially safer alternative to traditional gene editing for treating various CNS diseases. The program is currently in the research phase, leveraging nChroma Bio's platform for precise and tunable gene regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nChroma Bio CNS epigenetic editor program.